{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:43:14Z","timestamp":1773812594601,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Mycobacteriology section of the Department of Microbiology"}],"content-domain":{"domain":["tuberculosisjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.tube.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T03:36:30Z","timestamp":1522035390000},"page":"86-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of pyrosequencing for extensive drug resistance-defining anti-tuberculosis drugs for use in public healthcare"],"prefix":"10.1016","volume":"110","author":[{"given":"Remya","family":"Nambiar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daksha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanchan","family":"Ajbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mubin","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meeta","family":"Sadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmaja","family":"Keskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"van Belkum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2018.03.006_bib1","series-title":"Global tuberculosis report","year":"2016"},{"issue":"2","key":"10.1016\/j.tube.2018.03.006_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/0974-777X.81691","article-title":"Tuberculosis: current situation, challenges and overview of its control programs in India","volume":"3","author":"Sandhu","year":"2011","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.tube.2018.03.006_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13312-013-0021-4","article-title":"50 years of tuberculosis control in India: progress, pitfalls and the way forward","volume":"50","author":"John","year":"2013","journal-title":"Indian Pediatr"},{"issue":"2","key":"10.1016\/j.tube.2018.03.006_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/JCM.01821-13","article-title":"Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens","volume":"52","author":"Lin","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.tube.2018.03.006_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.03614-14","article-title":"Evaluation of pyrosequencing for detecting extensively drug-resistant tuberculosis (XDR-TB) in clinical isolates from four high-burden countries","volume":"59","author":"Ajbani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.03.006_bib6","series-title":"Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs","author":"WHO","year":"2008"},{"issue":"12","key":"10.1016\/j.tube.2018.03.006_bib7","first-page":"1449","article-title":"Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System","volume":"12","author":"Rodrigues","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"10.1016\/j.tube.2018.03.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0136861","article-title":"Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis","volume":"10","author":"Catanzaro","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.tube.2018.03.006_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0895-4356(93)90018-V","article-title":"Bias, prevalence and kappa","volume":"46","author":"Byrt","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.tube.2018.03.006_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01354-2017","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis","volume":"50","author":"Miotto","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2018.03.006_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tube.2014.11.003","article-title":"Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the Genotype MTBDRsl assay","volume":"95","author":"Kambli","year":"2014","journal-title":"Tuberculosis"},{"issue":"12","key":"10.1016\/j.tube.2018.03.006_bib12","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1128\/JCM.01229-09","article-title":"Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones","volume":"47","author":"Bravo","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.tube.2018.03.006_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1128\/AAC.01124-07","article-title":"Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations","volume":"52","author":"Gegia","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.tube.2018.03.006_bib14","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1128\/JCM.01239-11","article-title":"Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens","volume":"49","author":"Garc\u00eda-Sierra","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.tube.2018.03.006_bib15","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1128\/JCM.37.11.3578-3582.1999","article-title":"Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study","volume":"37","author":"Tortoli","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.tube.2018.03.006_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5588\/ijtld.16.0496","article-title":"Bottom-up or top-down: unit cost estimation of tuberculosis diagnostic tests in India","volume":"21","author":"Rupert","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.tube.2018.03.006_bib17","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.1128\/AAC.01117-15","article-title":"Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs","volume":"59","author":"Heysell","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147297921730478X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147297921730478X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T04:50:13Z","timestamp":1604033413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147297921730478X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":17,"alternative-id":["S147297921730478X"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2018.03.006","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of pyrosequencing for extensive drug resistance-defining anti-tuberculosis drugs for use in public healthcare","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}